ILLUMINATE : A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II trial is evaluating the safety and effectiveness of two immunotherapy drugs (durvalumab and tremelimumab) when given with chemotherapy for the treatment of EGFR mutant non-squamous non-small cell lung cancer (NSCLC).
 

This trial is treating patients with EGFR mutant non-squamous non-small cell lung cancer (NSCLC) .

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

Commercial Sponsor

AstraZeneca

Other Non-Commercial Sponsor

University of Sydney

Summary

All trial participants will commence with induction therapy. During induction, patients will receive 4 cycles of durvalumab (1500mg) and tremelimumab (75mg), in combination with cisplatin (75mg/m2) and pemetrexed (500mg/m2) via intravenous infusion every 3 weeks. Induction will be immediately followed by maintenance therapy, consisting of durvalumab (1500mg) and pemetrexed (500mg/m2) once every 4 weeks via intravenous infusion until disease progression or intolerance.

Recruiting Hospitals Read MoreRead more

St Vincent's Hospital, Medical and Radiation Oncology
Fitzroy
Ms Nadia Ranieri
oncology.research@svha.org.au
03 9288 3167

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next